Skip to Content

'
Matthew H.G. Katz, M.D., F.A.C.S.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1999 New York Medical College, New York, NY, MD, Alpha Omega Alpha, Doctor of Medicine
1994 University of California, Berkeley, CA, BA, Economics

Postgraduate Training

8/2006-7/2008 Clinical Fellowship, Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Steven Curley, MD
8/2002-7/2006 Postdoctoral Researcher, Moores Comprehensive Cancer Center, University of California, San Diego, CA, Michael Bouvet, MD
8/2000-7/2006 Categorical Residency, General Surgery, University of California, San Diego, CA
8/1999-7/2000 Clinical Internship, General Surgery, University of California, San Diego, CA

Experience/Service

Institutional Committee Activities

Member, Clinical Research Advisory Committee, 2015-present
Telemedicine Director, Minimally Invasive New Technology in Oncologic Surgery (MINTOS), 4/2013-present
Member, Concept Review Committee #3, 2013-2015
Education Co-Director, Minimally Invasive New Technology in Oncologic Surgery (MINTOS), 2012-2013
Member, Perioperative Value Analysis Team,The University of Texas MD Anderson Cancer Center, 2010-present
Member, Transfusions Committee, 2010-present
Member, Minimally Invasive New Technology in Oncologic Surgery (MINTOS), 2010-present

Honors and Awards

2016 Outstanding Teaching Award for Research, Awarded by Surgical Oncology Fellows, Department of Surgical Oncology, MD Anderson Cancer Center
2015-2016 NCI Cancer Clinical Investigator Team Leadership Award, National Cancer Institute
2015 Outstanding Teaching Award for Research, Awarded by Surgical Oncology Fellows, Department of Surgical Oncology, MD Anderson Cancer Center
2012-2014 Clinical Scholar Award in Recognition of Outstanding Achievement in Clinical Cancer Research, Alliance for Clinical Trials in Oncology
2012 MD Anderson Alumni and Faculty Association Mentorship Award

Selected Publications

Peer-Reviewed Original Research Articles

1. Katz MH, Shi Q, Ahmad SA, Herman JM, Marsh RW, Collisson E, Schwartz L, Frankel W, Martin R, Conway W, Truty M, Kindler H, Lowy AM, Bekaii-Saab T, Philip P, Talamonti M, Cardin D, LoConte N, Shen P, Hoffman JP, Venook AP. Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101. JAMA Surgery. e-Pub 6/2016. PMID: 27275632.
2. Cloyd JM, Crane CH, Koay EJ, Das P, Krishnan S, Prakash L, Snyder RA, Varadhachary GR, Wolff RA, Javle M, Shroff RT, Fogelman D, Overman M, Wang H, Maitra A, Lee JE, Fleming JB, Katz MH. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Cancer, 5/2016. PMID: 27243381.
3. Khorana AA, Mangu PB, Berlin J, Engebretson A, Hong TS, Maitra A, Mohile SG, Mumber M, Schulick R, Shapiro M, Urba S, Zeh HJ, Katz MH. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 5/2016. e-Pub 5/2016. PMID: 27247221.
4. Mise Y, Vauthey JN, Zimmitti G, Parker NH, Conrad C, Aloia TA, Lee JE, Fleming JB, Katz MH. Ninety-day Postoperative Mortality Is a Legitimate Measure of Hepatopancreatobiliary Surgical Quality. Ann Surg 262(6):1071-1078, 12/2015.
5. Schwarz L, Bruno M, Parker NH, Prakash L, Mise Y, Lee JE, Vauthey JN, Aloia TA, Conrad C, Fleming JB, Katz MH. Active Surveillance for Adverse Events Within 90 Days: The Standard for Reporting Surgical Outcomes After Pancreatectomy. Annals of Surgical Oncology 22(11):3522-3529, 10/2015. PMID: 25694246.
6. Cooper AB, Slack R, Fogelman D, Holmes HM, Petzel M, Parker N, Balachandran A, Garg N, Ngo-Huang A, Varadhachary G, Evans DB, Lee JE, Aloia TA, Conrad C, Vauthey JN, Fleming JB, Katz MHG. Characterization of anthropometric changes that occur during neoadjuvant therapy for potentially resectable pancreatic cancer. Annals of Surgical Oncology 22(7):2416-2423, 7/2015. PMID: 25519927.
7. Cooper AB, Holmes HM, des Bordes JKA, Fogelman D, Parker NH, Lee JE, Aloia TA, Vauthey JN, Fleming JB, Katz MH. The role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer. Journal of the American College of Surgeons 219(1):111-120, 3/2014.
8. Tran Cao HS, Balachandran A, Wang H, Nogueras-González GM, Bailey CE, Lee JE, Pisters PW, Evans DB, Varadhachary G, Crane CH, Aloia TA, Vauthey JN, Fleming JB, Katz MH. Radiographic Tumor-Vein Interface as a Predictor of Intraoperative, Pathologic, and Oncologic Outcomes in Resectable and Borderline Resectable Pancreatic Cancer. Journal of Gastrointestinal Surgery 18(2):269-278, 2/2014.
9. Tzeng CW, Katz MH, Fleming JB, Lee JE, Pisters PW, Holmes HM, Varadhachary GR, Wolff RA, Abbruzzese JL, Vauthey JN, Aloia TA. Morbidity and Mortality after Pancreaticoduodenectomy in Patients with Borderline Resectable Type C Clinical Classification. Journal of Gastrointestinal Surgery 18(1):146-155, 1/2014.
10. Tzeng CW, Cao HS, Lee JE, Pisters PW, Varadhachary GR, Wolff RA, Abbruzzese JL, Crane CH, Evans DB, Wang H, Abbott DE, Vauthey JN, Aloia TA, Fleming JB, Katz MH. Treatment Sequencing for Resectable Pancreatic Cancer: Influence of Early Metastases and Surgical Complications on Multimodality Therapy Completion and Survival. Journal of Gastrointestinal Surgery 18(1):16-24, 1/2014. PMCID: PMC24241967.
11. Lee S, Reha JL, Tzeng CWD, Massarweh NN, Chang GJ, Hetz SP, Fleming JB, Lee JE, Katz MH. Race does not impact pancreatic cancer treatment and survival in an equal access federal healthcare system. Annals of Surgical Oncology 20(13):4073-4079, 12/2013.
12. Katz MH, Marsh R, Herman JM, Shi Q, Collison E, Venook AP, Kindler HL, Alberts SR, Philip P, Lowy AM, Pisters PW, Posner MC, Berlin JD, Ahmad SA. Borderline Resectable Pancreatic Cancer: Need for Standardization and Methods for Optimal Clinical Trial Design. Ann Surg Oncol 20(8):2787-95, 8/2013. e-Pub 2/23/2013. PMID: 23435609.
13. Tzeng CW, Abbott DE, Cantor SB, Fleming JB, Lee JE, Pisters PW, Varadhachary GR, Abbruzzese JL, Wolff RA, Ahmad SA, Katz MH. Frequency and Intensity of Postoperative Surveillance After Curative Treatment of Pancreatic Cancer: A Cost-Effectiveness Analysis. Ann Surg Oncol 20(7):2197-203, 7/2013. e-Pub 2/14/2013. PMID: 23408126.
14. Petzel MQ, Parker NH, Valentine AD, Simard S, Nogueras-Gonzalez GM, Lee JE, Pisters PW, Vauthey JN, Fleming JB, Katz MH. Fear of cancer recurrence after curative pancreatectomy: a cross-sectional study in survivors of pancreatic and periampullary tumors. Annals of Surgical Oncology 19(13). e-Pub 8/2012.
15. Katz MH, Lee JE, Pisters PW, Skoracki R, Tamm E, Fleming JB. Retroperitoneal dissection in patients with borderline resectable pancreatic cancer: operative principles and techniques. J Am Coll Surg 215(2):e11-18, 8/2012.
16. Tzeng CW, Fleming JB, Lee JE, Wang X, Pisters PW, Vauthey JN, Varadhachary G, Wolff RA, Katz MH. Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy. HPB (Oxford) 14(6). e-Pub 6/2012.
17. Katz MH, Fleming JB, Bhosale P, Varadhachary G, Lee JE, Wolff R, Wang H, Abbruzzese J, Pisters PW, Vauthey JN, Charnsangavej C, Tamm E, Crane CH, Balachandran A. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer 118(23). e-Pub 5/2012.
18. Katz MH, Hu CY, Fleming JB, Pisters PW, Lee JE, Chang GJ. Clinical Calculator of Conditional Survival Estimates for Resected and Unresected Survivors of Pancreatic Cancer. Arch Surg 147(6). e-Pub 2/2012. PMID: 22351874.
19. Tzeng CW, Fleming JB, Lee JE, Xiao L, Pisters PW, Vauthey JN, Abdalla EK, Wolff RA, Varadhachary GR, Fogelman DR, Crane CH, Balachandran A, Katz MH. Defined Clinical Classifications Are Associated with Outcome of Patients with Anatomically Resectable Pancreatic Adenocarcinoma Treated with Neoadjuvant Therapy. Ann Surg Oncol 19(6). e-Pub 1/2012. PMID: 22258816.
20. Katz MH, Wang H, Balachandran A, Bhosale P, Crane CH, Wang X, Pisters PW, Lee JE, Vauthey JN, Abdalla EK, Wolff R, Abbruzzese J, Varadhachary G, Chopin-Laly X, Charnsangavej C, Fleming JB. Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer. J Gastrointest Surg 16(1):68-78; discussion 78-9, 1/2012. e-Pub 11/2011. PMID: 22065318.
21. Katz MH, Wolff R, Crane CH, Varadhachary G, Javle M, Lin E, Evans DB, Lee JE, Fleming JB, Pisters PW. Survival and Quality of Life of Patients with Resected Pancreatic Adenocarcinoma Treated with Adjuvant Interferon-Based Chemoradiation: A Phase II Trial. Annals of Surgical Oncology 18(13). e-Pub 6/2011. PMID: 21701927.
22. Katz MH, Merchant NB, Brower S, Branda M, Posner MC, William Traverso L, Abrams RA, Picozzi VJ, Pisters PW, The American College of Surgeons Oncology Group. Standardization of Surgical and Pathologic Variables is Needed in Multicenter Trials of Adjuvant Therapy for Pancreatic Cancer: Results from the ACOSOG Z5031 Trial. Ann Surg Oncol 18(2). e-Pub 9/2010. PMID: 20811779.
23. Tran Cao HS, Bouvet M, Kaushal S, Keleman A, Romney E, Kim G, Fruehauf J, Imagawa DK, Hoffman RM, Katz MH. Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer. Mol Cancer Ther 9(7):2068-78, 7/2010. e-Pub 7/2010. PMID: 20606044.

Books (edited and written)

1. Multiple authors. Ed(s) Katz MH, Ahmad S. Multimodality Management of Borderline Resectable Pancreatic Cancer. Springer, 2015.
2. Multiple authors. Ed(s) Nelson H, Hunt KK, Veeramachaneni N, Blair S, Chang G, Halverson A, Katz MH, Posner MC. Operative Standards for Cancer Surgery. Wolters Kluwer: Philadelphia, 2015.

Last updated: 8/1/2016